MAP4K

MAP4K Related Products (52):

By Effects:	Inhibitors (43) Antagonist (1) Degraders (3)

Cat. No.	Product Name	Effect	Purity

HY-135892

GNE-1858	Inhibitor	99.42%
GNE-1858 is a potent and ATP-competitive hematopoietic progenitor kinase-1 (HPK1) inhibitor, with IC₅₀s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively.

HY-146231A

SS47 TFA	Inhibitor	99.88%
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies. SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-123714

TL4-12	Inhibitor	99.82%
TL4-12 is a selective MAP4K2/GCK inhibitor, dose-dependently downregulates IKZF1 and BCL-6 and leads to MM cell proliferation inhibition (IC₅₀=37 nM) accompanied by induction of apoptosis. TL4-12 can be used to overcome immunomodulatory agent resistance in multiple myeloma (MM).

HY-138569

HPK1-IN-4	Inhibitor	99.42%
HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC₅₀ of 0.061 nM) as preclinical immunoresearch tool compound.

HY-156502

TINK-IN-1	Inhibitor	98.02%
TINK-IN-1 (Compound 9) is a potent and selective Traf2- and Nck-interacting kinase (TNIK) inhibitor with an IC₅₀ of 8 nM. TINK-IN-1 inhibits colorectal cancer cells viability.

HY-168972

Famlasertib	Inhibitor
Famlasertib (Prostetin/12k) is a potent, brain-penetrant inhibitor of mitogen-activated protein kinase kinase kinase kinase (MAP4K) family with an IC₅₀ value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.

HY-162922

MAP4K4-IN-6	Inhibitor
MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor (IC₅₀: 80 nM). MAP4K4-IN-6 reduces the c-Jun phosphorylation. MAP4K4-IN-6 has neuroprotective effects. MAP4K4-IN-6 increases the viability of motor neurons. MAP4K4-IN-6 can be used for research of Amyotrophic lateral sclerosis (ALS).

HY-173006

AZ3246	Inhibitor
AZ3246 is an orally active and selective inhibitor of HPK1 with an IC₅₀ < 3 nM. AZ3246 induces IL-2 secretion in T cells with an EC₅₀ of 90 nM. AZ3246 is a low-volume, low-clearance antitumor compound.

HY-132150A

HPK1-IN-2 dihydrochloride	Inhibitor	98.69%
HPK1-IN-2 dihydrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC₅₀<0.05 µΜ) with antitumor activity. HPK1-IN-2 dihydrochloride also inhibits Lck (0.05 µΜ<IC₅₀<0.5 µΜ) and Flt3 (IC₅₀<0.05 µΜ) kinase activities.

HY-145107

HPK1-IN-19	Inhibitor	98.04%
HPK1-IN-19 (Compound I-47) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor.

HY-159643

NDI-101150	Inhibitor
NDI-101150 is an orally active, potent and selective hematopoietic progenitor cell kinase 1 (HPK1) inhibitor. NDI-101150 enhances T cell activation and inhibits tumor growth.

HY-132926

HPK1-IN-8	Inhibitor	98.56%
HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length HPK1.

HY-149056A

(3S,4R)-GNE-6893	Inhibitor	99.49%
(3S,4R)-GNE-6893 is a potent and orally active HPK1 inhibitor. (3S,4R)-GNE-6893 can be used in research of cancer.

HY-145041

HPK1-IN-15	Inhibitor
HPK1-IN-15 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-15 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2018049200A1, compound 50).

HY-145042

HPK1-IN-16	Inhibitor
HPK1-IN-16 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-16 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019051199A1, compound 39).

HY-145039

HPK1-IN-13	Inhibitor
HPK1-IN-13 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-13 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 64) .

HY-145038

HPK1-IN-12	Inhibitor
HPK1-IN-12 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-12 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 85) .

HY-145044

HPK1-IN-17	Inhibitor
HPK1-IN-17 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-17 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019238067A1, compound 73).

HY-145040

HPK1-IN-14	Inhibitor
HPK1-IN-14 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-14 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 79) .

HY-145037

HPK1-IN-11	Inhibitor
HPK1-IN-11 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-11 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 2).

Name
Email *

	Sorry, but the email address you supplied was invalid.